BACKGROUND: The Malawian antiretroviral program uses generic Triomune (stavudine, lamivudine, and nevirapine). OBJECTIVE: To determine the pharmacokinetics and bioequivalence of generic and trade formulations of stavudine, lamivudine, and nevirapine in HIV-infected Malawians. METHODS: This randomized, open label, cross-over study comprised of six men and six women currently receiving Triomune-40 TM who were randomized to the generic or trade formulation of stavudine (40 mg twice daily), lamivudine (150 mg twice daily) and nevirapine (200 mg twice daily). After at least 21 days, the alternate formulation was administered. At the end of each period, six blood samples were collected over 8 h. Bioequivalence was achieved if the 90% confidence interval (CI) for the geometric mean ratio (GMR) of generic:trade formulations for maximum plasma concentration (Cmax) and the area under the concentration-time curve (AUC) was within 0.8-1.25. RESULTS:Mean patient age, weight, and height were 38.4 years (SD, 7.7), 71.2 kg (SD, 7.0), and 164.8 cm (SD, 6.3), respectively. The GMR for stavudine, lamivudine, and nevirapine were 1.4 (90% CI, 1.2-1.7), 1.1 (90% CI, 0.8-1.6), and 0.9 (90% CI, 0.7-1.2), respectively, for Cmax; and 1.1 (90% CI, 1.0 1.2), 1.0 (90% CI, 0.7-1.3), and 0.9 (90% CI, 0.7-1.1), respectively, for AUC0-8h. Regardless of formulation, Malawians had higher nevirapine exposures compared with historical reports of Western HIV-infected patients. CONCLUSIONS: Although exposures were similar, Triomune did not meet the strict definition of bioequivalence for these drugs. Patients taking Triomune had notably higher stavudine Cmax values. Antiretroviral pharmacokinetics and bioequivalence of generic formulations should be evaluated in the populations in which they are being used.
RCT Entities:
BACKGROUND: The Malawian antiretroviral program uses generic Triomune (stavudine, lamivudine, and nevirapine). OBJECTIVE: To determine the pharmacokinetics and bioequivalence of generic and trade formulations of stavudine, lamivudine, and nevirapine in HIV-infected Malawians. METHODS: This randomized, open label, cross-over study comprised of six men and six women currently receiving Triomune-40 TM who were randomized to the generic or trade formulation of stavudine (40 mg twice daily), lamivudine (150 mg twice daily) and nevirapine (200 mg twice daily). After at least 21 days, the alternate formulation was administered. At the end of each period, six blood samples were collected over 8 h. Bioequivalence was achieved if the 90% confidence interval (CI) for the geometric mean ratio (GMR) of generic:trade formulations for maximum plasma concentration (Cmax) and the area under the concentration-time curve (AUC) was within 0.8-1.25. RESULTS: Mean patient age, weight, and height were 38.4 years (SD, 7.7), 71.2 kg (SD, 7.0), and 164.8 cm (SD, 6.3), respectively. The GMR for stavudine, lamivudine, and nevirapine were 1.4 (90% CI, 1.2-1.7), 1.1 (90% CI, 0.8-1.6), and 0.9 (90% CI, 0.7-1.2), respectively, for Cmax; and 1.1 (90% CI, 1.0 1.2), 1.0 (90% CI, 0.7-1.3), and 0.9 (90% CI, 0.7-1.1), respectively, for AUC0-8h. Regardless of formulation, Malawians had higher nevirapine exposures compared with historical reports of Western HIV-infectedpatients. CONCLUSIONS: Although exposures were similar, Triomune did not meet the strict definition of bioequivalence for these drugs. Patients taking Triomune had notably higher stavudine Cmax values. Antiretroviral pharmacokinetics and bioequivalence of generic formulations should be evaluated in the populations in which they are being used.
Authors: Charles van der Horst; Charles Chasela; Yusuf Ahmed; Irving Hoffman; Mina Hosseinipour; Rodney Knight; Susan Fiscus; Michael Hudgens; Peter Kazembe; Margaret Bentley; Linda Adair; Ellen Piwoz; Francis Martinson; Ann Duerr; Athena Kourtis; A Edde Loeliger; Beth Tohill; Sascha Ellington; Denise Jamieson Journal: Contemp Clin Trials Date: 2008-09-07 Impact factor: 2.226
Authors: Kevin C Brown; Mina C Hosseinipour; Janelle M Hoskins; Ranjit K Thirumaran; Hsiao-Chuan Tien; Ralf Weigel; Jean Tauzie; Ida Shumba; Jatinder K Lamba; Erin G Schuetz; Howard L McLeod; Angela D M Kashuba; Amanda H Corbett Journal: Pharmacogenomics Date: 2011-11-23 Impact factor: 2.533
Authors: Adriana H Tremoulet; Mina Nikanjam; Tim R Cressey; Kulkanya Chokephaibulkit; Ross McKinney; Mark Mirochnick; Edmund V Capparelli Journal: J Clin Pharmacol Date: 2011-12-16 Impact factor: 3.126
Authors: Gretchen S Stuart; Agnes Moses; Amanda Corbett; Grace Phiri; Wiza Kumwenda; Nkhafwire Mkandawire; Joseph Chintedze; Gabriel Malunga; Mina Hosseinipour; Myron S Cohen; Frank Z Stanczyk; Angela D M Kashuba Journal: J Acquir Immune Defic Syndr Date: 2011-10-01 Impact factor: 3.731
Authors: Amanda H Corbett; Mina C Hosseinipour; Jean Nyirenda; Cecelia Kanyama; Naser L Rezk; Pax Mkupani; Dorothy Sichali; Hsiao Tien; Angela Dm Kashuba; Charles Mwansambo; Ralf Weigel; Peter Kazembe Journal: Antivir Ther Date: 2010
Authors: Awewura Kwara; Margaret Lartey; Isaac Boamah; Naser L Rezk; Joseph Oliver-Commey; Ernest Kenu; Angela D M Kashuba; Michael H Court Journal: J Clin Pharmacol Date: 2009-07-23 Impact factor: 3.126
Authors: Pauline Byakika-Kibwika; Mohammed Lamorde; Francis Kalemeera; Antonio D'Avolio; Sciandra Mauro; Giovanni Di Perri; Mairin Ryan; Harriet Mayanja-Kizza; Saye Khoo; David Back; Marta Boffito; Concepta Merry Journal: J Antimicrob Chemother Date: 2008-07-18 Impact factor: 5.790